IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-04-23 (biospace.com)
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. -
TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC for ArbliTM has indicated to Scienture that Saptalis has the materials and capabilities to produce the batches and supply product inventory in time for the target commercial launch.
Read more
2025-03-31 (scientificinquirer.com)
A Costly Cure? Trump's "Liberation Day" Tariffs Threaten U.S. Drug Supply Chains - Scientific Inquirer
Trump's impending tariffs may threaten U.S. drug supply, particularly generics from Canada, risking shortages and higher consumer costs.
Read more
2024-02-05 (pressetext.com)
Growth of the drug market significantly slowed by price cuts
In 2023, the Swiss medicines market had a turnover of 7.4 billion francs, or +4.9% (at factory prices). Although demand for medicines increased, price reductions reduced growth by 2.7%.
Read more
2024-02-05 (med-technews.com)
IQVIA report finds Cyted technology reduces endoscopies demand
An independent assessment by analytics provider IQVIA in partnership with NHS England has found that Cyted’s diagnostic technology reduced the demand for endoscopies in secondary care by 78%, improved the patient experience and decreased costs.
Read more
2023-12-04 (managedhealthcareexecutive.com)
IQVIA: Drug Shortages are Growing
Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.
Read more
2023-11-21 (pharmexec.com)
The Impact of US Drug Shortages on the Supply Chain
IQVIA report explores why these shortages are increasing, and how they can be mitigated.
Read more
2023-11-21 (pharmaceuticalcommerce.com)
An Examination of US Drug Shortages’ Impact on the Supply Chain
IQVIA report explores why these shortages are increasing, and how they can be mitigated.
Read more
2022-11-15 (axios.com)
America’s Adderall shortage
A rise in demand for Adderall has triggered a shortage of the drug.
Read more